UTRECHT, The Netherlands--(BUSINESS WIRE)--AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today provided a business update and the outcome from ...
Phase 3 REVIVAL study stopped per recommendation of data monitoring committee after per-protocol pre-specified interim futility analysis on the study's primary endpoint, 28-day mortality, without any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results